Catalent (NYSE:CTLT) has seen a shortfall of 780,011 shares or 13% in the short interest. The remaining shorts are 5% of the total floated shares. The net short interest, as on June 15,2016, stood at 5,199,850 shares and the stocks days to cover will be 2 by factoring in the average per day volume of 2,408,726 shares. On May 31,2016, 5,979,861 shares were shorted. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Catalent (NYSE:CTLT): The stock opened at $22.89 on Friday but the bulls could not build on the opening and the stock topped out at $23.20 for the day. The stock traded down to $22.53 during the day, due to lack of any buying support eventually closed down at $22.79 with a loss of -3.68% for the day. The stock had closed at $23.66 on the previous day. The total traded volume was 2,796,287 shares.
The company shares have dropped -22.59% from its 1 Year high price. On Aug 5, 2015, the shares registered one year high at $34.42 and the one year low was seen on Feb 10, 2016. The 50-Day Moving Average price is $25.07 and the 200 Day Moving Average price is recorded at $25.51.
Stocks of Catalent (NYSE:CTLT) rallied by 6.3% during the past week but lost 21.39% on a 4-week basis. The company has outperformed the S&P 500 by 8.06% in the past week but underperformed the index by 19.01% in the last 4 weeks.
Catalent, Inc. is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Companys segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecules lifecycle. The Medication Delivery Solutions segment provides formulation, development and manufacturing services for delivery of drugs and biologics, administered through injection, inhalation and ophthalmic routes, using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing, packaging, storage and inventory management for drugs and biologics in clinical trials.